SEC Form 4 · accession 0001209191-19-006857
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nassim Usman
Officer — President & CEO · Director
Period of report
Jan 31, 2019
Accepted (ET)
Feb 4, 2019 · 4:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 31, 2019 | M | 5,729 | $4.63 | A | 11,041 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.63 | Jan 31, 2019 | M | 5,729 | D | — | Jul 11, 2027 | Common Stock | 5,729 | 269,271 | D |
Explanation of responses
- F1The Option vests monthly over a period of four years commencing June 15, 2017